XBiotech (XBIT) Current Deferred Revenue (2019 - 2020)

XBiotech (XBIT) posted quarterly Current Deferred Revenue of $1.5 million for Q1 2020, down 66.67% quarter-over-quarter from $4.5 million in Q4 2019.

XBiotech (XBIT) Current Deferred Revenue (2019 - 2020) Analysis & Trends

XBiotech's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $1.5 million for Q1 2020.

In Q1 2020, Current Deferred Revenue changed N/A year-over-year to $1.5 million; the TTM figure through Mar 2020 stood at $1.5 million (changed N/A YoY), while the FY2019 annual figure was $4.5 million, changed N/A from the prior year.
Current Deferred Revenue for Q1 2020 stood at $1.5 million, down from $4.5 million in the prior quarter.
The five-year high for Current Deferred Revenue was $4.5 million in Q4 2019, with the low at $1.5 million in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	XBiotech	68.90 Mn	68.90 Mn	-

Download Data